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A B S T R A C T
Objectives: The aim of this cross-sectional study was to describe the results of a systematic serological
screening programme for strongyloidiasis.
Methods: A prospective serological screening programme for strongyloidiasis was performed between 2009
and 2014forall immigrantpatientsattendingtheTropical Medicine Unit.Threeformalin-etherconcentrated
stool samples and an ELISA for anti-Strongyloides stercoralis antibodies were used as screening tools.
Results: Of 659 patients screened, 79 (12%) were positive for S. stercoralis regardless of the diagnostic
method used. The prevalence of infection was 42.9% in East African patients, 16.3% in Central African
patients,10.9% in those from South America, and 10% in the case of West Africa. Univariate analysis showed
that infection by S. stercoralis was significantly more frequent in patients from Central Africa (p = 0.026; OR
1.72, 95% CI 1.03–2.85) and East Africa (p < 0.001; OR 5.88, 95% CI 1.75–19.32). Taking West Africa as the
reference (as the area of lowest prevalence among the positive prevalence areas), the statistical analysis
showed that the risk of infection was higher in East Africa (p = 0.001; OR 6.750, 95% CI 2.127–21.423) and
Central Africa (p = 0.065; OR 1.747, 95% CI 0.965–3.163).
Conclusions: Due to the potential complications of strongyloidiasis infection, we recommend that
immigrant patients from developing countries be routinely screened for S. stercoralis, especially those from
East Africa. A serological test is a highly appropriate screening tool.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Strongyloidiasis is a soil-transmitted helminth infection caused
by the nematode Strongyloides stercoralis and is endemic mainly in
tropical and subtropical regions, but also in temperate regions
(Schär et al., 2013). This parasitosis is widely extended all over the
world. It is estimated that at least 370 million individuals are
infected worldwide, with a high degree of endemic burden in the* Corresponding author at: Unidad de Enfermedades Infecciosas, Hospital
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).tropical zones, especially Southeast Asia, Sub-Saharan Africa, and
Latin America (Schär et al., 2013; Monge-Maillo et al., 2018; Bisoffi
et al., 2013).
Distinctive characteristics of this parasite are its ability to
persist and replicate within a host for life and its potential to cause
life-threatening infection in the immunocompromised host. In
normal healthy individuals, the infection is usually asymptomatic
or causes no specific or intermittent clinical symptoms (Bisoffi
et al., 2013). However, in the presence of certain predisposing
conditions such as immunosuppression due to the use of steroids,
kidney allograft recipients, and patients with lymphoma, the
disease may change to forms of hyper-infection or disseminated
types of strongyloidiasis (Bisoffi et al., 2013).
As strongyloidiasis persists for life, it can cause serious
morbidity or death long after an immigrant resettles in a new
country. For this reason it has been suggested that it is necessary to
conduct screening of newly arrived (i.e., within 5 years), high-riskciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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technique (Monge-Maillo et al., 2018; Boggild et al., 2016; Díaz-
Menéndez et al., 2012).
Since 2009, the Unit of Tropical Medicine of the Hospital
Universitario Central de Asturias (Spain) has performed a
screening test for S. stercoralis infection for all immigrant patients.
The aims of this cross-sectional study were to describe the
results of a systematic serological screening programme for
strongyloidiasis and to identify the geographic areas with the




This prospective screening programme for strongyloidiasis was
performed within the screening programme for parasitic diseases
in the adult immigrant population. All immigrant patients
attending the Tropical Medicine Unit of the Hospital Universitario
Central de Asturias, a reference centre in a region of northern Spain
where 3.8% of the population is foreign-born, were screened,
regardless of their origin (Spanish Statistical Institute, 2019).
Screening took place between January 2009 and December 2014.
All patients were given an epidemiological questionnaire that
included demographic variables such as sex, age, country of origin,
classical risk factors for the disease (walking with bare feet, contact
with human waste or contaminated soil, immunosuppression),
presence of symptoms, and time from arrival in Spain to first
consultation at the Tropical Medicine Unit.
The patients were classified into seven groups according to
their geographical area of origin (Central Africa, East Africa, West
Africa, North Africa, Mexico and Central America, South America,
and South Asia), following the US Centers for Disease Control and
Prevention (CDC) criteria (CDC, 2019).
Only subjects who had not received any anthelmintic treatment
within the previous 2 years were included in the study.
Laboratory diagnosis protocol
Three formalin-ether concentrated stool samples and an ELISA
for anti-S. stercoralis antibodies were used as the screening tools.
The qualitative detection of IgG antibodies to S. stercoralis was done
using an ELISA (DRG Diagnostics) with microwells coated with
Strongyloides antigen.
It is known that Strongyloides serology may have cross-reactions
with filarial worms and other intestinal helminths such as
hookworm species (Yori et al., 2006). For this reason, a blood
sample was taken from all patients of Sub-Saharan origin, for the
detection of microfilaremia. The diagnosis of filariasis was made
through observation of the parasite after a concentration
technique with 2% formalin (Knott technique). The species
diagnosis was done by Giemsa staining.
A patient was considered as positive if at least one of the
diagnostic tests used for screening (stool samples or/and ELISA)
was positive. The patients with S. stercoralis and mixed infection
with other filarial worms or nematodes were excluded from the
study. An eosinophil blood count was performed for all patients.
Eosinophilia was defined as >500 eosinophils/mm3. All positive
patients were treated with ivermectin (200 mg/kg for 2 days).
Statistical analysis
Age was described by mean and standard deviation, while the
time in Spain was described using the median and range. The non-
parametric Mann–Whitney test was used for comparisons.Categorical variables were described by absolute and relative
frequencies. In the analysis of geographical distribution, only
regions that registered positive for the S. stercoralis parasite were
considered. The region with the smallest observed prevalence was
used as the reference region.
The exact Chi-square test was used to contrast relationships
between categorical variables. In addition, exact binomial 95%
confidence intervals (CI) were computed for the Strongyloides
prevalence rates. Univariate and multivariate logistic regression
analyses were used to compute crude and adjusted odds ratios
(OR), respectively.
Ethics statement
The study presented in this paper forms part of an overall
project entitled “Study of prevalence of imported diseases in an
immigrant population”, which was approved by the Ethics
Committee of Clinical Investigation of Asturias.
Results
During the study period, 659 patients were screened (mean age
34  12 years; 50.4% female). Seventy per cent of patients had lived
in Spain for more than 1 year. The areas of origin were Central
Africa (30.9%), West Africa (30.4%), South America (28%), North
Africa (5.3%), East Africa (2.1%), Mexico and Central America (1.8%),
and South Asia (1.5%). The most frequent countries of origin were
Equatorial Guinea (28.7%), Senegal (19.3%), and Ecuador (12%).
Table 1 shows the geographical distribution and prevalence of
strongyloidiasis by geographical area. The univariate analysis
showed that a positive result for S. stercoralis was significantly
more frequent in patients from Central Africa (p = 0.026; OR 1.72,
95% CI 1.03–2.85) and East Africa (p < 0.001; OR 5.88, 95% CI 1.75–
19.32).
Taking West Africa as the reference (as the area of lowest
prevalence among positive prevalence areas), the statistical
analysis showed that the risk of infection was higher in East
Africa (p = 0.001; OR 6.750, 95% CI 2.127–21.423) and Central Africa
(p = 0.065; OR 1.747, 95% CI 0.965–3.163). When the risk of infection
was adjusted for sex and age, it was observed that it decreased
significantly: from 6.750 to 5.070 in East Africa and from 1.747 to
1.314 in Central Africa. When adjusting for underlying diseases, the
risk decreased in Central Africa (1.151, p = 0.702), and only East
Africa remained as a risk area (5.298, p = 0.007) (Table 2).
Seventy-nine patients (12%, 95% CI 9.43–14.54%) had a positive
serological test for S. stercoralis; microscopic visualization of larvae
of S. stercoralis by formalin-ether concentration of faeces was
positive for only four of them. There was no statistically significant
difference in relationship with age or time in Spain between the
positive and negative patients. On the other hand, females had
more strongyloidiasis than males (p = 0.005). The characteristics of
Strongyloides and non-Strongyloides infected patients are shown in
Table 1.
When information about risk factors was examined, it was seen
that all Strongyloides-positive patients had been walking with bare
feet, most of them in areas with mud. One patient had an HIV
infection with a CD4+ count of 366 cells/mm3 at the time of
diagnosis. The most frequent symptoms were abdominal pain
(60%) and diarrhoea (18%). Three patients described itching and
one patient had an urticariform rash. No patient described
respiratory diseases. Twenty-two patients (28.6%) were asymp-
tomatic, although 10 of them had eosinophilia. Overall, 30% of
patients had eosinophilia, with a mean cell count of 1063  2076
cells/mm3. All patients diagnosed with S. stercoralis were treated
with ivermectin and none of the patients developed clinical
complications.
Table 2
Global and adjusted risk of infection for geographic area.
Origin Number (%) Model 1 Model 2 Model 3
OR (95% CI) OR (95% CI) OR (95% CI)
West Africa 20 (10%) 1 1 1
Central Africa 33 (16.3%) 1.747 (0.965–3.163) 1.314 (0.666–2.593) 1.151 (0.560–2.367)
East Africa 6 (42.9%) 6.750 (2.127–21.423) 5.070 (1.530–16.804) 5.298 (1.581–17.749)
South America 20 (10.9%) 1.098 (0.570–2.113) 0.867 (0.420–1.789) 0.858 (0.410–1.798)
OR, odds ratio; CI, confidence interval.
Model 1: global risk of infection by geographic area.
Model 2: risk of infection by geographic area adjusted for age and sex.
Model 3: risk of infection by geographic area adjusted for age, sex, and underlying diseases.
Table 1
Comparison of the characteristics between Strongyloides and non-Strongyloides infected patients.
Characteristics Non-Strongyloides group (n = 580) Strongyloides group (n = 79) Univariate analysis
p-Value OR (95% CI)
Demographic characteristics
Sex, male/female 299/281 28/51 0.005
Age (years) 34.24 (12.085) 32.67 (12.314) 0.335 NS
Average time in Spain (days) 1133 (788) 981.71 (839.30) 0.673 NS
Area of origin
Central Africa 171 (30%) 33 (42%) 0.026 1.72 (1.03–2.85)
West Africa 180 (31%) 20 (25%) 0.299 NS
South America 164 (28%) 20 (25%) 0.30 NS
North Africa 35 (6%) 0 (0%) 0.024 0.00 (0.00–0.99)
East Africa 8 (1.4%) 6 (8%) 0.0003 5.88 (1.75–19.32)
Mexico and Central America 12 (2%) 0 (0%) 0.196 NS
South Asia 10 (1.6%) 0 (0%) 0.239 NS
Country of origina
Equatorial Guinea 156 33 0.003 2.02 (1.21–3.37)
Senegal 120 7 0.012 2.68 (1.15–6.55)
Ecuador 67 13 0.210 NS
Brazil 21 1 0.274 NS
Ivory Coast 6 2 0.254 NS
Guinea Conakry 16 2 0.907 NS
Nigeria 22 6 0.116 NS
Paraguay 10 4 0.053 0.33 (0.09–1.28)
Mauritania 2 1 0.253 NS
Ethiopia 2 4 0.00003 15.41 (2.38–123.3)
Gambia 1 1 0.225 NS
Argentina 6 2 0.254 NS
Ghana 6 1 0.225 NS
Kenya 2 2 0.072 NS
Underlying diseases
HIV infection 23 2 0.757 NS
Chronic hepatitis B 46 5 0.617 NS
Hepatitis C 18 7 0.011 3.04 (1.11–8.04)
HTLV 0 1 0.184 NS
Asymptomatic 221 22 0.018 1.751 (1.098–2.79)
OR, odds ratio; CI, confidence interval; NS, not significant; HTLV, human T-lymphotropic virus. Data are presented as n (%), or as the mean (standard deviation).
a Only countries with positive cases.
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S. stercoralis is a nematode with a worldwide distribution,
although it is particularly prevalent in regions of Africa, Southeast
Asia, and Latin America (Schär et al., 2013). Its ability to propagate
in the host by internal autoinfection results in chronic infection
that can last for life. More than 50% of patients with chronic
infection are asymptomatic, while others may show non-specific
cutaneous, gastrointestinal, or pulmonary symptoms (Puthiya-
kunnon et al., 2014). Consequently, strongyloidiasis is frequently a
chronic but unrecognized infection of immigrant populations in
developed countries (Monge-Maillo et al., 2018; Díaz-Menéndez
et al., 2012; Salvador et al., 2019). In previous studies performed in
Spain in 14 centres, S. stercoralis was diagnosed in nearly 1% of
travellers, 6% of immigrants, and 9.7% of visiting friends and
relatives of immigrants 5]. Therefore, it appears necessary to
conduct screening for S. stercoralis in the population coming fromendemic areas (Monge-Maillo et al., 2018; Boggild et al., 2016;
Díaz-Menéndez et al., 2012; Salvador et al., 2019; Agbata et al.,
2018; Requena-Méndez et al., 2017; Caruana et al., 2006). However,
the selection of the method to be used for screening is
controversial. Studies using stool microscopy have reported
prevalence rates (0.8% to 4.3%) lower than those obtained when
serological enzyme immunoassays are used (9% to 77%) (Biggs
et al., 2009; Requena-Méndez et al., 2013; Lifson et al., 2002;
Martin and Mak, 2006; Miller et al., 2000; Rice et al., 2003).
The definitive diagnosis of strongyloidiasis is usually made on
the basis of the detection of larvae in the stool. In patients with
strongyloidiasis, larval output in stools is often low, and
microscopic examination of a single stool sample is negative in
up to 70% of cases (Requena-Méndez et al., 2013; Buonfrate et al.,
2015; Bisoffi et al., 2014; Inês Ede et al., 2011). Several techniques
have been used to discern larvae in stool samples, including direct
smear of faeces in saline–Lugol iodine stain, Baermann
L. Casado et al. / International Journal of Infectious Diseases 88 (2019) 60–64 63concentration, formalin-ethyl acetate concentration, Harada–Mori
filter paper culture, and nutrient agar plate cultures. The most
sensitive morphological method is the agar plate technique.
However, it is expensive, requires fresh faeces, and takes several
days to obtain a result (Buonfrate et al., 2015; Bisoffi et al., 2014;
Inês Ede et al., 2011).
Serology has been used for screening and diagnosis, as well as
post-treatment monitoring, alone or in combination with stool
testing,and is considered by some authorsto be the method of choice
for screening due to its higher sensitivity compared to stool
examination (Boggild et al., 2016; Biggs et al., 2009; Inês Ede
et al., 2011;Centers forDisease Control and Prevention,2018; Murray
et al., 2019; Sudarshi et al., 2003). Nevertheless, the predictive value
in high-risk populations is limited due to the cross-reactivity with
other helminth infections (Murray et al., 2019). So, co-infection with
filarial worms or other nematodes must be excluded.
The seroprevalence of strongyloidiasis depends on the meth-
odology used and the origin of the population studied. Studies
performed in South Asian immigrants have shown seroprevalence
rates of 24–65% (Monge-Maillo et al., 2018; Díaz-Menéndez et al.,
2012; Salvador et al., 2019; Lifson et al., 2002; Miller et al., 2000).
An infection rate of 39% for Strongyloides infection was found in
asymptomatic refugees with eosinophilia originating from diverse
regions, who were evaluated serologically (Seybolt et al., 2006).
Other series performed in African patients have reported
seroprevalence rates of strongyloidiasis of 12–17% 18,19], as found
in this study. In the present study, migrants from Ethiopia, Nigeria,
Paraguay, and Equatorial Guinea showed prevalence rates of 18–
66%, but significant differences between countries were not found,
probably due to the low number of cases. In other studies, the
prevalence in these areas varied from 25% in Nigeria (Sanyaolu
et al., 2011) to 2% and 5% in Brazil (De Assis and de Olivieria, 2013).
Although a prevalence of between 7% and 13% has been reported in
Ethiopia (Getaneh et al., 2010; Berger et al., 1989), the Ethiopian
immigrant population in the present study showed a prevalence of
66%, the highest of the countries studied.
Infections with S. stercoralis can be asymptomatic or lead to
cutaneous, gastrointestinal, or pulmonary symptoms, although in
many cases, eosinophilia is the only indication of its presence.
Several approaches have been tried for the screening and
treatment of these patients based on the presence of eosinophilia.
Canadian clinical guidelines for immigrants and refugees consider
testing foreign-born individuals for strongyloidiasis if they have
lived in areas of the world where these parasites are endemic and
(1) have compatible signs and/or symptoms of infection and/or (2)
have evidence of peripheral blood eosinophilia (Boggild et al.,
2016). It is noteworthy that only 30% of the present study patients
presented blood eosinophilia, which was the only finding in 10 of
them. These results show a poor correlation between serological
positivity and the presence of blood eosinophilia, perhaps because
eosinophilia typically occurs in response to tissue invasion by a
parasite, so occurs intermittently and may be missed if only a
single complete blood count (CBC) is examined. This suggests that
the eosinophil count in peripheral blood is not sensitive enough to
be used as a sole initial screening test, as has been supported by
several studies (Seybolt et al., 2006).
On the other hand, due to documented high rates of infection in
refugee populations and its serious clinical consequences, the CDC
have recommended pre-departure treatment for strongyloidiasis
with two doses of ivermectin for refugees from non-Loa loa
endemic countries and albendazole in those from countries with
endemic Loa loa (Centers for Disease Control and Prevention,
2018). This approach could be difficult in the case of illegal
immigrants without pre-departure counselling, and treatment
with albendazole in possible Loa loa patients is a less effective
option than ivermectin for strongyloidiasis.There are limitations to this study. It is possible that, despite the
attempt to exclude the presence of other parasitic diseases, we
overestimated the prevalence of Strongyloides due to cross-
reactions with undetected infections. The presence of undiagnosed
S. stercoralis is of particular concern, due to the potential serious
clinical complications, such as hyper-infestation syndrome. This
syndrome is characterized by infective filariform larvae in the stool
and sputum, leading to clinical manifestations of increased
parasite load and migration (such as gastrointestinal bleeding,
respiratory distress, and septic shock) (Buonfrate et al., 2013).
Active screening and treatment of at-risk groups eradicates
infection and eliminates the risk of future severe complications,
including death.
Thus, we recommend that immigrant patients from developing
countries be routinely screened for S. stercoralis, especially those
from East Africa. Due to the low sensitivity of stool examination for
ova and parasites arising from low larval burden and intermittent
shedding in the stool, serological testing is the diagnostic method
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